p53 Accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting

Journal of Urology

Volumn 164, Issue 3 I, 2000, Pages 716-721

  Borre, Michael ^a   Stausbøl Grøn, Birgitte ^a   Overgaard, Jens ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bcl 2; Biological; Genes; P53; Prostate; Prostatic neoplasms; Tumor markers

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; DISEASE ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; STAINING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033897377     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)67288-6     Document Type: Article

References (49)

1. Fibiger, J. and Trier, S.: Bericht über die Zählung der am 1. April 1908 in Dänemark in ärztlicher Behandlung gewesenen Krebskranken. Z Krebsforschung, 9: 275, 1910
2. Borre, M., Nerstrøm, B. and Overgaard, J.: The dilemma of prostate cancer. A growing human and economic burden irrespective of treatment strategies. Acta Oncol, 36: 681, 1997
3. Engeland, A., Haldorsen, T., Tretli, S. et al: Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. APMIS, 38: 64, 1993
4. Engeland, A., Haldorsen, T., Tretli, S. et al: Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival analysis. A collaborative study of the five Nordic Cancer Registries. APMIS, suppl., 49: 1, 1995
5. Borre, M., Nerstrøm, B. and Overgaard, J.: The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer, 80: 917, 1997
6. Mettlin, C., Jones, G. W. and Murphy, G. P.: Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin, 43:83, 1993
7. Harris, A. L.: Mutant p53: the commonest genetic abnormality in human cancer? J Pathol, 162: 5, 1990
8. Bartek, J., Bartkova, J., Vojtesek, B. et al: Abberant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene, 6: 1699, 1991
9. Gannon, J. V. and Lane, D. P.: Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature, 349: 802, 1991
10. Isobe, M., Emanuel, B. S., Givol, D. et al: Localization of the gene for human p53 tumour antigen to band 17p13. Nature, 320: 84, 1986
11. Levine, A. J., Momand, J. and Finlay, C. A.: The p53 tumour suppressor gene. Nature, 351: 453, 1991
12. Vogelstein, B. and Kinzler, K. W.: p53 function and dysfunction. Cell, 70: 523, 1992
13. Lane, D. P.: p53, guardian of the genome. Nature, 358:15, 1992
14. Yonish-Rouach, E., Grunwald, D., Wilder, S. et al: p53-mediated cell death: relationship to cell cycle control. Mol Cell Biol, 13: 1415, 1993
15. Vojtesek, B., Bartek, J., Midgley, C. A. et al: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods, 151: 237, 1992
16. Navone, N. M., Troncoso, P., Pisters, L. L. et al: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst, 85: 1657, 1993
17. Shurbaji, M. S., Kalbfleisch, J. H. and Thurmond, T. S.: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol, 26: 106, 1995
18. Apakama, I., Robinson, M. C., Walter, N. M. et al: bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer, 74:1258, 1996
19. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K et al: p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res, 1: 1295, 1995
20. Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K et al: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated localized prostate cancer. J Urol, 156: 1511, 1996
21. Stricker, H. J., Jay, J. K., Linden, M. D. et al: Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology, 47: 366, 1996
22. Bubendorf, L., Sauter, G., Moch, H. et al: Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol, 148: 1557, 1996
23. Yang, G., Stapleton, A. M., Wheeler, T. M. et al: Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin Cancer Res, 2: 399, 1996
24. Byrne, R. L., Home, C. H., Robinson, M. C. et al: The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol, 79: 190, 1997
25. Matsushima, H., Kitamura, T., Goto, T. et al: Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol, 158: 2278, 1997
26. Theodorescu, D., Broder, S. R., Boyd, J. C. et al: p53, bcl2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol, 158: 131, 1997
27. Stapleton, A. M., Zbell, P., Kattan, M. W. et al: Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery, Cancer, 82: 168, 1998
28. Brewster, S. F., Oxley, J. D., Trivella, M. et al: Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predic-tors of biochemical relapse after radical prostatectomy. J Urol, 161:1238, 1999
29. Scherr, D. S., Vaughan, E. D., Jr., Wei, J. et al: BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol, 162:12, 1999
30. Cheng, L., Sebo, T. J., Cheville, J. C. et al: p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer, 85: 1293, 1999
31. Stackhouse, G. B., Sesterhenn, I. A., Bauer, J. J. et al: p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol, 162: 2040, 1999
32. Berner, A., Harvei, S., Tretli, S. et al: Prostatic carcinoma: a multivariate analysis of prognostic factors. Br J Cancer, 69: 924, 1994
33. Stattin, P., Bergh, A., Karlberg, L. et al: p53 immunoreactivity as prognostic marker for cancer-specific survival in prostate cancer. Eur Urol, 30: 65, 1996
34. Brooks, J. D., Bova, G. S., Ewing, C. M. et al: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res, 56: 3814, 1996
35. Kerr, J. F., Wyllie, A. H. and Currie, A. R.: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer, 26: 239, 1972
36. Borre, M., Stausbøl-Grøn, B., Nerstrøm, B. et al: Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly. Prostate Cancer Prostatic Dis, 5: 268, 1998
37. Borre, M., Bentzen, S. M. Nerstrøm, B. et al: Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol, 159: 1609, 1998
38. Cattoretti, G., Becker, M. H., Key, G. et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol, 168: 357, 1992
39. Hockenbury, D., Nunøez, G., Millimam, C. et al: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348: 334, 1990
40. Jacobs, T. W., Prioleau, J. E., Stillman, I. E. et al: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst, 88:1054, 1996
41. Byar, D. P. and Mostofi, F. K.: Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Examined by the step-section technique. Cancer, 30: 5, 1972
42. Borre, M., Offersen, B. V., Nerstrøm, B. et al: Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer, 78: 940, 1998
43. Johnson, M. I., Robinson, M. C., Marsh, C. et al: Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. Prostate, 37: 223, 1998
44. Heidenberg, H. B., Bauer, J. J., McLeod, D. G. et al: The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology, 48: 971, 1996
45. Elledge, R. M., Clark, G. M., Fuqua, S. A. et al: p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. Cancer Res, 54: 3752, 1994
46. Fisher, C. J., Gillett, C. E., Vojtesek, B. et al: Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer, 69: 26, 1994
47. Elledge, R. M.: Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick? J Natl Cancer Inst, 88: 141, 1996
48. Papadopoulos, I., Rudolph, P., Wirth, B. et al: p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Urology, 48: 261, 1996
49. Moul, J. W., Bettencourt, M-C., Sesterhenn, I. A. et al: Protein expression of p53, bcl-2, and Ki-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery, 120:159, 1996